Global Staphylococcal Infection Drugs Market Size By Product (Beta-lactams, Peptides, Quinolones), By Competitive Landscape, By Geographic Scope And Forecast

Staphylococcal Infection Drugs Market Size And Forecast

Staphylococcal Infection Drugs Market size is projected to grow at a CAGR of 3% from 2019 to 2026.

The Global Staphylococcal Infection Drugs Market has witnessed strong growth owing to the increasing incidence of staphylococcal infections, Inventions of new drug classes and vaccines, increase in community-associated non-invasive MSSA infections, and uplifting patent trends. The Global Staphylococcal Infection Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Staphylococcal Infection Drugs Market Definition

Staphylococcus infection is mainly caused by staph or staphylococcus bacteria. The infections differ from simple boil to antibiotic-resistant infections to flesh-eating infections. This sort of infection is very popular in the general population and people with low immune systems. People with diabetes or weakened immunity are especially prone to expanding this infection. Treatment of a staph infection involves antibiotics, wound drainage, and device removal.

Skin infections are the most popular form of the staphylococcal disease. External infections may be diffuse, with vesicular pustules and crusting (impetigo) or sometimes cellulitis, or focal with nodular sores (furuncles and carbuncles). Deeper cutaneous abscesses are also popular. Moreover, the increased incidence of staphylococcal infections is mainly due to the development of antibiotic-resistant staphylococcal strains like Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA).

Global Staphylococcal Infection Drugs Market Overview

The Global Staphylococcal Infection Drugs Market is principally driven by an increase in community-associated non-invasive MSSA infections and uplifting patent trends. The development of antibiotic-resistant strains has led to an enhanced incidence of staphylococcal infections. Skin and soft tissue diseases are the most popular type of infections caused by staphylococcal. Thus, the increasing incidence of staphylococcal infections is a significant driver contributing to market growth. Similarly, electrochemical phenotyping is further gaining popularity for identifying antibiotic-resistant bacteria.

These excellent screening technologies will help in recognizing rare antibiotic-resistant mutants and support the development of novel drugs. The development of excellent technologies to screen antibiotic-resistant strains will be a significant trend that will have a definite impact on the growth of the Staphylococcal Infection Drugs Market. However, unlike most infectious diseases that can be stopped by vaccines, there is no licensed vaccine for the prevention of staphylococcal infections.

The accelerated evolution of the bacteria responsible along with the subsequent factors poses a significant hurdle to the growth of vaccines against staphylococcal infections. Moreover, a lack of awareness also restrains the growth of the market. According to the estimation of "Centre of Disease Control Has Prevention", it has been observed that more than 119,000 bloodstream staph infections transpired in 2017, nearly 20,000 people died from bloodstream staph infections in 2017 and 2016, 9% of all dangerous staph-infected people injected drugs raised from 4% in 2011.

Global Staphylococcal Infection Drugs Market: Segmentation Analysis

The Global Staphylococcal Infection Drugs Market is segmented on the basis of Product And Geography.

Staphylococcal Infection Drugs Market, By Product

• Beta-lactams
• Peptides
• Quinolones
• Macrolides
• Others

Based on Product, the market is bifurcated into Beta-lactams, Peptides, Quinolones, Macrolides, and Others. The peptide segment is estimated to witness the highest CAGR for the forecast period. Peptides are the best alternatives to conventional antibiotics for tackling the issue of bacterial multidrug resistance. The Beta-lactams segment is also expected to grow at a considerable rate during the forecast period.

Staphylococcal Infection Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Regional Analysis, the Global Staphylococcal Infection Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. It has been identified that Asia will estimate the largest Staphylococcal Infection Drugs Market share during the forecast period. The growth of the segment is attributed to the growing use of antibiotics in countries such as China and India, the huge prevalence of staphylococcal infection, and the increasing awareness about the necessity to manage and prevent infectious diseases.

Key Players

The "Global Staphylococcal Infection Drugs Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as The Medicines Company, Theravance Biopharma, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.